Oman Healthcare Market Report 2026: Pharmaceutical Intelligence, MOH Access, and Vision 2040 Strategy

The Oman healthcare market is estimated at USD 5.5–6.5 billion in 2026, growing at approximately 6.2% CAGR through 2030. Government healthcare expenditure accounts for approximately 70% of total spend, funded through Oman's oil revenues and supplemented by growing employer and private health insurance. Oman's population of 4.9 million — including a large expatriate workforce — creates a diverse healthcare demand profile.

The Oman pharmaceutical market is estimated at USD 520–580 million in 2026, growing at 6.5–7% CAGR. MOH Central Medical Stores supplies government hospitals; private pharmacies and private hospital chains serve the remainder. Oman imports approximately 97% of pharmaceutical requirements — local manufacturing is limited to a small number of generic producers. Branded specialty pharmaceuticals in oncology, diabetes, and cardiovascular disease represent the highest-value market segments.

The Directorate General of Pharmaceutical Affairs and Drug Control at MOH Oman manages drug registration. Registration follows a technical dossier review process aligned with WHO standards; CE or FDA clearance and reference registration in ICH countries expedite review. Timelines range from 12–24 months for initial registration. Formulary listing at MOH Central Medical Stores follows registration and requires a local agent with an active import license. BioNixus tracks MOH Oman registration status and formulary listing timelines across therapeutic categories.

Oman pharmaceutical market growth is driven by: (1) chronic disease burden — diabetes (19%), cardiovascular disease, and cancer incidence all exceed global averages; (2) Vision 2040's commitment to expanding health insurance coverage to all Oman residents, increasing retail pharmacy channel value; (3) private hospital sector growth as Aster, Badr Al Samaa, and international hospital groups expand specialty capacity; and (4) increased awareness and early diagnosis driven by national screening programs.

Oncology is Oman's fastest-growing pharmaceutical therapy area — the Sultan Qaboos Comprehensive Cancer Care and Research Centre expansion is creating new consumption capacity. Diabetes management (GLP-1 receptor agonists, insulin intensification) is structurally large given ~19% adult prevalence. Rare diseases have growing attention through Royal Hospital's genetics program. Immunology and biologics are expanding as private insurance formularies broaden coverage of specialty drugs.

Oman introduced Dhamani, its mandatory health insurance scheme for private-sector employees and their dependents, in 2021, formalizing a channel that had previously been fragmented across employer-arranged policies. Dhamani-compliant insurers must offer a minimum benefits package that increasingly includes outpatient pharmaceuticals, chronic disease management, and specialist referrals, expanding the addressable market beyond MOH facilities alone. Private hospitals such as Al Shifa Hospital and Muscat Private Hospital rely heavily on Dhamani-linked reimbursement to fund specialty drug formularies that would otherwise be constrained by out-of-pocket affordability. For pharmaceutical manufacturers, insurer formulary inclusion is now a parallel access pathway alongside MOH Central Pharmacy listing, particularly for chronic and specialty therapies favored by private-sector and expatriate patients. BioNixus tracks Dhamani-linked insurer formulary decisions alongside MOH listing status to give clients a complete view of Oman market access.

MOH Oman actively promotes generic substitution to manage its pharmaceutical import bill, given that Oman imports approximately 97% of its medicines and has limited local manufacturing capacity. Generic registration follows an abbreviated dossier pathway referencing bioequivalence data, which typically completes faster than the 18–30 month innovator registration timeline. Biosimilars are registered under a comparability framework aligned with WHO and GCC guidance, though physician and patient acceptance in specialty categories such as oncology and immunology remains an ongoing education need at Royal Hospital and SQUH. MOH tender procurement frequently favors the lowest-cost qualified generic or biosimilar supplier for high-volume chronic disease categories including diabetes and cardiovascular therapies. Originator manufacturers competing in Oman should expect generic and biosimilar entry to compress volumes materially within 12–24 months of patent expiry or loss of exclusivity in most therapeutic classes.

Clinical research in Oman is anchored by Sultan Qaboos University Hospital, which combines academic research infrastructure with a national genomics and oncology research agenda. MOH's Research and Studies Department, together with institutional ethics committees at SQUH and Royal Hospital, reviews clinical trial protocols against ICH-GCP standards, though overall trial volume remains modest relative to Saudi Arabia and the UAE. Investigator-initiated and multinational Phase III trials in oncology, diabetes, and cardiovascular disease represent the bulk of current activity, reflecting the country's dominant disease burden. Vision 2040's emphasis on building a knowledge-based healthcare economy is gradually increasing government support for local research capacity and international trial partnerships. Manufacturers evaluating Oman as a trial site benefit from smaller, well-characterized patient registries and strong specialist engagement at the country's principal referral hospitals.

BioNixus delivers longitudinal hospital consumption analogue analytics, payer and formulary committee qualitative boards, bilingual HCP trackers where relevant, tender and access intelligence aligned to MOH registration and hospital procurement at The Royal Hospital and national centres in Oman, KOL mapping, and adoption modelling for healthcare and life sciences. Teams receive decision-ready outputs cross-validated against EphMRA and BHBIA governance with GDPR-aligned multinational fieldwork coordinated from London and regional hubs.